Monitoring Agency Report for the quarter ended 31st March, 2026
SMSPHARMA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
SMS Pharmaceuticals Limited has submitted the Monitoring Agency Report (by CARE Ratings Limited) for Q4FY26, confirming full utilization of Rs. 114.30 crore raised via preferential issuance of convertible share warrants (issued March 7-13, 2024). Funds were deployed across three objects: Capital Expenditure (Rs. 63.41 crore vs. Rs. 62.87 crore planned), Working Capital (Rs. 40.00 crore as planned), and General Corporate Purposes (Rs. 10.89 crore vs. Rs. 11.43 crore planned). The Monitoring Agency noted a minor inter-object reallocation of Rs. 0.54 crore from GCP to Capex, staying within the ±10% shareholder-approved threshold. No material deviations were reported, no delays were observed, and all statutory approvals were in place. The entire issue proceeds have been fully deployed by March 31, 2026.
The completion of warrant proceeds utilization with only minor, shareholder-approved fund reallocations is a positive signal. It indicates the company executed its stated capital plans without major slippages, which is reassuring for investors tracking how preferential issue funds were deployed.